检索结果-南通市图书馆

酒．饮料技术装备 2002年第4期 27-30页

作者：刘尚义

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

merlin:抢救性PCI的预后

中国介入心脏病学杂志 2004年第5期12卷 300-300页

作者：余国膺

ST段抬高的心肌梗死(MI)病人溶栓失败后抢救性PCI的结果如何?随机性临床试验．MERI心(Middesbrough Early Revaseularization to Limit InfarelJon)的结果反映，短期内提高无事件的生存率，但并不提高总的生存率。介入治疗病人脑卒中较... 详细信息

ST段抬高的心肌梗死(MI)病人溶栓失败后抢救性PCI的结果如何?随机性临床试验．MERI心(Middesbrough Early Revaseularization to Limit InfarelJon)的结果反映，短期内提高无事件的生存率，但并不提高总的生存率。介入治疗病人脑卒中较多，需输血者较多，并未能保持左室收缩功能。

关键词： merlin 抢救性PCI 预后心肌梗死临床试验

维普期刊数据库

merlin全新的组合式8-up CTP系统

在线全文

学校读者我要写书评

暂无评论

今日印刷 1998年第4期 90-90页

作者：吴畏

丹麦Purup-Eskofot公司新近推出了一种全新的大对开内滚筒式可直接出软片和印版的直接制版机merlin,其输出幅面可达820mm×1080mm,并提供可由客户指定的头、尾打孔功能,采用氩离子激光曝光,具有1270dpi、2540dpi和3175dpi三级可调分辨率... 详细信息

丹麦Purup-Eskofot公司新近推出了一种全新的大对开内滚筒式可直接出软片和印版的直接制版机merlin,其输出幅面可达820mm×1080mm,并提供可由客户指定的头、尾打孔功能,采用氩离子激光曝光,具有1270dpi、2540dpi和3175dpi三级可调分辨率。merlin的操作系统为一种专用的控制软件Purup-Eskofot Commander,它可以在显示照排机配置、静态参数等的同时显示正在曝光的工作状态。

关键词：上版 up CTP 过稿软片印版 merlin 照排机照相排字机版材

merlin-Gerin公司铸造生产的发展:法国公司经营活动研究:述评

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

管理观察 1997年第4期 13-13页

作者：陈云卿

维普期刊数据库

笔记本电脑和手持PC的无线PC卡调制解调器merlin无线PC卡

在线全文

学校读者我要写书评

暂无评论

电子测试 2000年第12期13卷 92-92页

EH101“灰背隼”（merlin）直升机

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

航空知识 1996年第8期 50-50页

天高海阔任悠游NOVATEL merlin G201 GPRS PCMCIA卡

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

新潮电子 2002年第7期 58-58页

新型抗缺血药物治疗急性冠状动脉综合征的评价:雷诺嗪用于减少非ST段抬高型急性冠状动脉综合征局部缺血的代谢效能(merlin)-TIMI36试验的试验设计与原理

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（心脏病学分册） 2006年第11期2卷 18-18页

作者： Morrow D.A. Scirica B.M. Karwatowska-Prokopczuk E. 罗亮 TIMI Study Group Cardiovascular Division Department of Medicine Boston MA United States Dr.

Background: Despite advances in antithrombotic therapies and invasive technology, the risk of recurrent ischemic complications in patients with non-ST-elevation acute coronary syndromes(NSTE-ACSs) remains substantial. Ranolazine is a novel agent that inhibits the late sodium current thereby reducing cellular sodium and calcium overload and has been shown to reduce ischemia in patients with chronic stable angina. Study Design: merlin-TIMI 36 is a phase III, randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy and safety of ranolazine during long-term treatment of patients with NSTE-ACS receiving standard therapy(N=6500). Eligible patients are randomized 1 ∶1 to ranolazine or matched placebo, initiated as 200 mg intravenously over 1 hour, followed by an 80-mg/h infusion(40 mg/h for patients with severe renal insufficiency) for up to 96 hours and oral ranolazine ER 1000 mg BID or matched placebo until the end of study. The primary end point is the time to first occurrence of any element of the composite of cardiovascular death, myocardial infarction, or recurrent ischemia. Secondary end points include ischemia on Holter monitoring, hospitalization for new or worsening heart failure, quality of life measures, and exercise performance. The evaluation of longterm safety will include death from any cause and symptomatic documented arrhythmia. Recruitment began in October 2004. The trial will continue until 730 major cardiovascular events and 310 deaths are recorded with expected completion in 24 to 28 months. Conclusions: merlin-TIMI 36 will evaluate the role of ranolazine in the acute and chronic management of patients presenting with NSTE-ACS.

关键词： merlin ST段抬高 TIMI36 雷诺嗪局部缺血药物治疗试验设计长期安全性次要终点

维普期刊数据库

DCAF1 (VprBP): emerging physiological roles for a unique dual-service E3 ubiquitin ligase substrate receptor

在线全文

学校读者我要写书评

暂无评论

Journal of Molecular Cell Biology 2019年第9期11卷 725-735页

作者： N.Max Schabla Koushik Mondal Patrick C.Swanson Department of Medical Microbiology and Immunology Creighton University2500 California PlazaOmahaNE 68178USA Present address:Institute of Cellular and Molecular Immunology Georg-August-University of GottingenMedical FacultyHumboldtallee 3437073 GottingenGermany Present address:Department of Ophthalmology Hamilton Eye InstituteUniversity of Tennessee Health Sciences Center930 Madison AvenueMemphisTN 38163USA

Cullin-RING ligases(CRLs)comprise a large group of modular eukaryotic E3 ubiquitin *** this family,the CRL4 ligase(consisting of the Cullin4[CUL4]scaffold protein,the Rbxl RING finger domain protein,the DNA damage-binding protein 1[DDB1],and one of many DDBl-associated substrate receptor proteins)has been intensively studied in recent years due to its involvement in regulating various cellular processes,its role in cancer development and progression,and its subversion by viral accessory *** discovered as a target for hijacking by the human immunodeficiency virus accessory protein r,the normal targets and function of the CRL4 substrate receptor protein DDBl-Cul4-associated factor 1(DCAF1;also known as VprBP)had remained elusive,but newer studies have begun to shed light on these ***,we review recent progress in understanding the diverse physiological roles of this DCAF1 in supporting various general and cell type-specific cellular processes in its context with the CRL4 E3 ligase,as well as another HECT-type E3 ligase with which DCAF1 also associates,called EDD/*** also discuss emerging questions and areas of future study to uncover the dynamic roles of DCAF1 in normal physiology.

关键词： V(D)J recombination merlin Dicer p53 EDD/DYRK2 TET Hippo

The CREB-Binding Protein Inhibitor Underlying a Promising Therapeutic Strategy in NF2-associated Meningioma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The CREB-Binding Protein Inhibitor Underlying a Promising Th...